App-Quantinova.ai

Venous Thromboembolism Prophylaxis Practices for Patients with Sickle Cell Disease Pre and during the COVID-19 Pandemic

Jennifer G. Davila - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

A Comparison of Scoring Systems for Predicting HIT in CABG Patients

Marwah W Farooqui - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Heparin

Circulating Histone Levels Correlate with the Severity of COVID-19 and the Extent of Coagulation Activation and Inflammation

Rebecca Jane Shaw - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

Fibrinogen (IV)

Bleeding in Patients with Clinically Severe Von Willebrand Disease: Preliminary Results of Athn 9, a Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Severe Von Willebrand Disease (VWD)

Angela C. Weyand - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Design of the Von Willebrand Factor in Pregnancy (VIP) Study

Jill M Johnsen - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Tranexamic acid

Real-World Clinical Outcomes in Previously Untreated and Minimally Treated Patients with Congenital Factor VIII Deficiency: The San Diego Experience

Kelly A Bush - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

FVIII

Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity

Andrew Johnsrud - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

Axicabtagene ciloleucel

Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy

Eric S. Mullins - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Venous thrombosis

FVIII

Gut Microbiota Dysbiosis and Elevated Lipopolysaccharide Serum Levels Are Associated with Venous Thromboembolism in Pediatric Patients

Rida Abid Hasan - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Venous thrombosis

Evithrom

Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma

Anna L. Parks - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication

Darko Antic - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Thrombosis and Mortality in Pregnant Patients with COVID-19

Elizabeth Behrens - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

N/A

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients

Farah Ashraf - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

dipyridamole

Anticoagulant Usage Patterns for Acute Venous Thromboembolism in Patients with Advanced Liver Disease

Amar H Kelkar - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Venous thrombosis

N/A

Retrospective Real-World Analysis of the Primary Safety Outcomes in Venous Thromboembolism of High-Risk Major Bleeding Cancer Patients Receiving Therapeutic Anticoagulation

Eric Brucks Brucks - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

rivaroxaban

Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy

Desiree Campoy - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

rivaroxaban

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19

Rodolfo Jimnez-Soto - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Venous thrombosis

Enoxaparin

Risk of Recurrent Venous Thromboembolism and Bleeding in Patients with Cancer Associated Thrombosis

Doaa Attia - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Impact of Platelet Count on Bleeding in the Setting of Anti-Platelet Therapy

Robert Hugh Lee - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

Clopidogrel bisulfate

Development and Baseline Characterization of a Thrombosis Risk Alert Tool: A Quality Assessment Project

Claire M Sathe - American Society of Hematology (ASH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Venous thrombosis

N/A

Filters

7277 Abstracts